O
NAUT icon

OrbiMed’s Nautilus Biotechnolgy NAUT Stock Holding History

OrbiMed’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,452,774
Closed -$7.53M – 158
2021
Q4 		$7.53M Hold
1,452,774
– – 0.1% 126
2021
Q3 		$8.92M Sell
1,452,774
-93,926
-6% -$748K 0.1% 133
2021
Q2 		$15.6M Buy
1,546,700
+1,497,325
+3,033% +$16.2M 0.16% 105
2021
Q1 		$680K Buy
+49,375
New +$684K 0.01% 156

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

OrbiMed's NAUT Position: Q1 2022 in Review

OrbiMed sold out of Nautilus Biotechnolgy (NAUT) in Q1 2022, closing a stake of 1,452,774 shares — an estimated $7.53M sold.

OrbiMed first reported a position in NAUT in Q1 2021 and held it in 4 quarters. The position peaked at $15.6M in Q2 2021. 82 funds tracked by Wall St. Rank hold NAUT as of Q1 2022.

  • OrbiMed reported no remaining Nautilus Biotechnolgy position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 1,452,774 Nautilus Biotechnolgy shares in Q1 2022, an estimated $7.53M.
  • OrbiMed first reported a position in Nautilus Biotechnolgy in Q1 2021 and held it in 4 quarters.
  • OrbiMed's Nautilus Biotechnolgy position peaked at $15.6M in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.